GSK Ris-Rez B7-H3 ADC Osteosarcoma Phase 3: Second Tumor Win

Update September 27, 2026: Merck and Daiichi Sankyo withdrew the I-DXd BLA for ES-SCLC on September 25 after the FDA said the Phase 2 IDeate-Lung01 data do not support accelerated approval (see our withdrawal coverage). That removes I-DXd as the would-be first B7-H3 ADC on the market, which is a modest positive for Ris-Rez’s positioning.

GSK’s (GSK) licensor Hansoh Pharmaceutical Group announced on July 28, 2026 that ARTEMIS-011, a Phase 3 trial of risvutatug rezetecan (Ris-Rez, HS-20093, GSK5764227) in relapsed osteosarcoma, met its primary endpoint of progression-free survival. The B7-H3-targeted antibody-drug conjugate (ADC) showed statistically significant and clinically meaningful PFS improvement compared with chemotherapy, with consistent benefit across secondary endpoints including overall survival. The safety profile was consistent with prior findings, and no new safety signals emerged. The full press release is on GSK’s site.

GSK closed at $51.98, down $0.05 on the day. The move was negligible for a company with a market cap exceeding $100 billion.

ARTEMIS-011 enrolled patients in China who had relapsed after at least two prior lines of systemic therapy. Hansoh will use the data for a regulatory submission in China. GSK holds exclusive worldwide rights outside mainland China, Hong Kong, Macau, and Taiwan, and is running EMBOLD Sarcoma-202, a global Phase 1b/2 trial in previously treated sarcomas including osteosarcoma.

What B7-H3 is and why it matters

B7-H3 is a cell-surface protein overexpressed across a wide range of solid tumors but with limited expression on normal tissues, making it an attractive ADC target. Ris-Rez pairs a fully human anti-B7-H3 monoclonal antibody with a topoisomerase inhibitor payload. When the antibody binds B7-H3 on a tumor cell, the ADC is internalized and releases the payload inside the cell, killing it from within.

The ARTEMIS-011 result is the second positive Phase 3 for Ris-Rez after ARTEMIS-008, which hit its primary endpoint in advanced or relapsed small-cell lung cancer (SCLC). That makes Ris-Rez the only B7-H3-targeted ADC to deliver positive Phase 3 outcomes across multiple tumor types.

The B7-H3 target is competitive. Daiichi Sankyo’s ifinatamab deruxtecan (I-DXd), co-developed with Merck, had a PDUFA date of October 10, 2026 for previously treated extensive-stage SCLC, but the companies withdrew the BLA on September 25 after the FDA said the Phase 2 IDeate-Lung01 data do not support accelerated approval. That removes I-DXd as the would-be first B7-H3 ADC on the market. GSK’s Ris-Rez, with two Phase 3 wins and an FDA Breakthrough Therapy Designation in osteosarcoma, is now the clinical leader in breadth of proof. For more on the broader ADC competitive picture, see our ADC stocks analysis.

Why osteosarcoma matters

Osteosarcoma is the most common primary bone cancer, mainly affecting children and young adults, with a global incidence of approximately 3.4 cases per million people per year. After patients progress on two prior lines of treatment, there are no approved therapies. The FDA granted Breakthrough Therapy Designation to Ris-Rez in relapsed or refractory osteosarcoma in January 2025.

The China-only Phase 3 means a US approval is not imminent. GSK’s global program (EMBOLD Sarcoma-202) is still in Phase 1b/2, and a global registrational trial has not yet launched. The ARTEMIS-011 data de-risk the target and the drug, but US investors are buying a 2028 or later timeline, not a near-term catalyst.

What to watch

The next catalyst for Ris-Rez is the full ARTEMIS-011 data presentation, expected at a medical congress. Investors should watch for the PFS hazard ratio and median figures, which the press release did not disclose. The specific risk for GSK is that the China-only data may not transfer cleanly to a global population, and the FDA typically requires registrational data from trials that include US sites. Until EMBOLD Sarcoma-202 reads out or GSK initiates a global Phase 3, the US regulatory path remains speculative.

What It Means for the Trade

Two Phase 3 wins across two tumor types makes Ris-Rez the breadth leader in a target class whose first-mover just stepped aside — and that is the trade. Daiichi Sankyo/Merck’s I-DXd had an October 10 PDUFA in SCLC but was withdrawn on September 25, clearing the way for GSK to potentially lead the class. GSK holds the deeper Phase 3 evidence base plus a Breakthrough Therapy Designation in osteosarcoma, an indication with no approved therapy after two prior lines. For a $100 billion-plus stock at $51.98, none of this moves the near-term numbers; what it does is build out the post-2028 oncology story GSK needs as older assets age. The timeline is the key discipline for investors: ARTEMIS-011 is China-only, EMBOLD Sarcoma-202 is Phase 1b/2, and no global registrational trial has launched — US filing timelines run to 2028 or later.

Mechanism and Market Context

B7-H3 is an immune-checkpoint-family protein overexpressed broadly in solid tumors — including lung, prostate, and sarcoma subtypes — with limited normal-tissue expression, the ideal ADC target profile: enough tumor specificity for a potent payload, enough prevalence for franchise economics. Ris-Rez links a fully human anti-B7-H3 antibody to a topoisomerase-inhibitor payload, the same payload class that powers the leading ADC franchises, internalized after binding and released inside the tumor cell. The competitive frame within B7-H3 is now two-horse — I-DXd withdrawn in SCLC, Ris-Rez holding the multi-tumor proof — and the class question is whether B7-H3 becomes the next HER2-scale ADC franchise or a niche, with the osteosarcoma and SCLC labels deciding the floor.

Risks and What Could Go Wrong

1. China-only registrational data may not satisfy FDA evidentiary expectations; a global Phase 3 must run before any US filing, pushing revenue past 2028.
2. I-DXd’s October 10 filing was withdrawn September 25, which removes a first-mover but leaves the SCLC B7-H3 label open for whoever gets to market next.
3. Topoisomerase-payload ADCs carry class-wide myelosuppression and interstitial lung disease risks that grow with broader tumor use.